BioSpace News Archive

Avenue Therapeutics, Inc., a company focused on the development of intravenous tramadol for the U.S. market, announced that its Phase 1 data on intravenous tramadol has been published in the peer-reviewed journal Clinical Pharmacology in Drug Development.

Agreement adds 350 premium tumor PDX models to world’s largest PDX collection

Phase II randomized trial led by investigators at Fox Chase Cancer Center will look at chemotherapy combinations for people with stage IV non-squamous non-small cell lung cancer with EGFR mutation or who never smoked

Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time on Tuesday, November 12, 2019

The patent will be in effect until at least 2034.

Allergan plc announced that its subsidiaries, Forest Laboratories, LLC, Forest Laboratories, Inc. and Forest Laboratories Holdings Ltd. have reached a resolution with a plaintiff class of direct purchasers of Namenda, concluding the previously disclosed direct purchaser class action litigation in the U.S. District Court for the Southern District of New York.

Data on lead program demonstrated that glucocorticoids promote prostate tumor cell growth, stimulate androgen-regulated gene expression, and drive resistance to enzalutamide, effects that were completely reversed by ORIC-101

Centogene has applied to list its common shares on the Nasdaq Global Market under the symbol “CNTG.”

Rafael Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced the milestone activation of 25 sites for its pivotal Phase 3 clinical trial (ARMADA 2000) of CPI-613® (devimistat) in patients with relapsed or refractory acute myeloid leukemia (AML).

Connects with leading telehealth companies to make it easier for Members to access virtual acute and primary care clinicians